The global situation right now is a moving target, forcing many business owners to hope for the best and prepare for the ...

Dozens of people testified before the House Ways and Means Committee Thursday to request the committee to either continue to ...

With interest in a papal elections high thanks to the Oscar-nominated film “Conclave, ” Pope Francis threw a wrench Thursday ...

The 10% tariffs on Chinese goods began Tuesday. China reacted with a 15% tariff on coal and liquefied natural gas and a 10% tariff on crude oil, agricultural machinery, large-displacement automobiles ...

Cardinal Health (NYSE:CAH – Get Free Report) had its price target upped by equities researchers at Wells Fargo & Company from ...

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Cencora simplifies distribution logistics by shipping products to centralized wholesaler locations, as opposed to shipping directly to pharmacies and various customer locations. Additionally, Cencora ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.

Several prospects are on the rise and the Cardinals are about to find out which ones are ready for the big-league fire.